SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced of a potential partnership with Novo Nordisk to distribute GLP-1 obesity drugs, signaling an end to their prior legal dispute. This development has ignited fervent community discussion about a massive short squeeze due to the stock's high short interest and its strengthened position in the digital health market.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after forming a partnership with Hims & Hers to distribute its obesity drugs, ending a prior feud and surprising the community. This, alongside reports of rapidly accelerating oral Wegovy prescriptions and an FDA crackdown on compounded GLP-1s, is driving discussion that the stock is oversold despite ongoing competitive dynamics with Eli Lilly.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as it announces a $300 million restructuring charge, fueling speculation among investors about a potential exit from its struggling Converse brand. The community remains divided, with many concerned about ongoing margin pressures and the slow pace of a turnaround, while others see a long-term buying opportunity despite confusing price action around recent tariff news.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's Day 74 Letter confirming MOLBREEVI's Biologics License Application is under full review with a PDUFA target action date of August 22, 2026, and no advisory committee meeting planned. The community sees this as a positive step towards Molbreevi becoming a first-in-class therapy for autoimmune PAP, fueling optimism around its market potential and future valuation.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Rithm Capital is actively discussed for its impending S&P SmallCap 600 index inclusion, which analysts anticipate will trigger substantial institutional buying, alongside its consistent earnings beats and strategic evolution into a diversified asset manager. The community is vigorously debating the stock's significant undervaluation and the potential for a future C-Corp conversion or spin-off to unlock considerable shareholder value.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating U.S.-Iran tensions have severely disrupted oil tanker traffic through the Strait of Hormuz, propelling crude prices higher. The community is split between calls for further parabolic gains to $150-$200 due to broken supply chains and warnings of a manipulated "blow-off top" and imminent correction, with broader concerns about inflation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

Will Nasdaq ETFs Continue Their Rally Going Into Q2 Earnings?

QQQ, QQQM, QQEW, QQQJ and QQQE surge as Nasdaq hits highs on earnings momentum, AI optimism and rate cut hopes.

Nasdaq Turns Positive in 2025: ETFs to Ride the Rally

Logitech International S.A. (LOGI) division Streamlabs announced substantial enhancements to its AI-powered streaming assistant on Tuesday, ahead of its full-scale launch, which is anticipated later in 2025.&nbsp;The latest version of the Streamlabs Intelligent Streaming Agent was showcased at Computex, highlighting a leap in live content creation and audience engagement capabilities for streamers.The upgraded platform integrates advanced systems developed by NVIDIA Corp. (NVDA) and the narrative-focused AI engine Inworld AI.&nbsp;Designed to respond instantly to live gameplay and viewer engagement, the system allows for a more interactive and immersive streaming experience.The latest capabilities enable content creators to streamline elements of their livestreams using real-time, context-sensitive triggers, executing tasks like switching scenes, playing sound effects, or having the avatar speak tailored messages, eliminating the need for manual intervention.The refined Streaming Agent empowers creators with advanced avatar customization, letting them tailor personality, voice, and expressions using NVIDIA's digital human tools and Inworld AI.&nbsp;It also acts as a real-time assistant, offering technical guidance and creative support drawn from a knowledge base, helping streamers of all skill levels navigate live broadcasts more effectively.&nbsp;“Together with NVIDIA and Inworld AI, we’re advancing interactive technology to help streamers engage with their audiences in new and creative ways,” said Head of Streamlabs, Ashray Urs.&nbsp;“The tools we’re unveiling today represent an entirely new era of digital storytelling, and the new demo at Computex is a crucial step closer to bringing these solutions to market at scale.”The upgrade also improves how streamers connect with their audiences through chat.&nbsp;The assistant can now generate quick recaps for viewers who join late and launch interactive polls that let the audience influence decisions mid-stream.&nbsp;On Stocktwits, sentiment around Logitech improved from ‘bearish’ to ‘neutral’.<figure class="image"><img style="aspect-ratio:632/75;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_20_071509_png_fb3b91ea6e.webp" alt="Screenshot 2025-05-20 071509.png" width="632" height="75"><figcaption>LOGI's Sentiment Meter and Message Volume as of 07.30 a.m. ET on May 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/LOGI">Logitech</a> stock has&nbsp;gained 5% in 2025 but shed 3.7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-india-ambitions-gain-momentun-with-foxconn-s-1.5-b-investment/ch0doKSRb8x">Apple’s India Ambitions Gain Momentum As Foxconn Invests $1.5B In Local iPhone Assembly Arm</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Logitech company logo is seen displayed on a smartphone screen.

Logitech’s Streaming Agent Gets Smarter, More Personal: Retail Sentiment Improves 

The upgraded AI assistant provides real-time automation, avatar customization, and interactive tools to boost livestream production and audience engagement.

Equity

The upgraded AI assistant provides real-time automation, avatar customization, and interactive tools to boost livestream production and audience engagement.


Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a settlement payment with the National Institutes of Health, drawing a cautious response from retail investors.The payment reportedly comprises $750 million as a settlement for claimed royalties during calendar years 2020-2023, and $41.5 million consideration for the NIH towards an amended and restated license agreement, dated December 20.BioNTech, a clinical-stage biotechnology company, focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases.BioNTech had been in discussions with the National Institutes of Health concerning royalties and other amounts allegedly owed on certain sales along with its collaboration partner Pfizer in connection to COVID-19 vaccine, the Fly.com reported.Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.<stembedurl>https://stocktwits.com/taxplanr/message/597983247</stembedurl> <stembedurl>https://stocktwits.com/taxplanr/message/597861544</stembedurl> &nbsp;The Fly.com report said the company's execution of the settlement agreement wasn’t an admission of liability as the company denied it had any legal liabilities or was in violation of any laws.NIH has reportedly agreed to consider any alleged noncompliance under the amended license agreement to be resolved for the period up to and including January 1, 2024, including any claimed historical royalty payments allegedly owed by the company prior to January 1, 2024.In parallel, BioNTech and the NIH also entered into the amended license agreement that provides a “framework” for a license for use in combination products including the COVID-19 vaccine used in combination with other active pharmaceutical ingredients.The settlement agreement requires Pfizer to reimburse BioNTech for $364.5 million of the claimed royalties paid to the NIH for 2020-2023 sales, the report added.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious

Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

Chinese search engine and artificial intelligence (AI) company Baidu, Inc. (<a class="mention" data-mention="$BIDU" data-symbol-id="BIDU" href="https://stocktwits.com/symbol/BIDU" target="_blank">$BIDU</a>) reported sub-par third-quarter earnings amid weakness in its core online marketing business.Beijing, China-based Baidu reported third-quarter non-GAAP earnings per ADS of 16.60 yuan or $2.37, marking a 19% year-on-year (YoY) decline and a 21% sequential drop. Analysts, on average, estimated 17.90 yuan per ADS for the quarter, according to Yahoo Finance.Total revenue slipped 3% YoY and 1% sequentially to 33.56 billion yuan or $4.78 billion, slightly ahead of the 33.43-billion-yuan consensus estimate polled by LSEG, according to Reuters.Baidu Core revenue was flat YoY to 26.5 billion yuan, with online marketing revenue slipping 4% to 18.8 billion yuan. The decline was offset by a 12% increase in online non-marketing revenue, driven by the AI Cloud business.Revenue from iQIYI, Baidu’s&nbsp;Chinese subscription video on-demand over-the-top streaming service, fell 10% to 7.2 billion yuan.Commenting on the quarterly performance, Robin Li, CEO of Baidu said, "Core's flattish third quarter top line reflected the ongoing weakness in our online marketing business, offset by the growth of our AI Cloud business."Li, however, said Baidu’s AI&nbsp; capabilities are gaining broader market recognition, as evidenced by increasing adoption of the ERNIE humanoid robot.&nbsp;The company’s robotaxi service “Apollo Go” has achieved another milestone with its sixth-generation autonomous vehicle RT6, which is now operating on public roads across multiple Chinese cities, he added.Rides provided by Apollo Go's fully driverless vehicles accounted for over 70% of total rides nationwide in the third quarter, rising further to 80% in October."Despite the near-term pressures, we remain steadfast in our AI-focused strategy and are confident in our long-term trajectory," Li said.Interim CFO Junjie He said core operating margins remained stable as the company managed to further optimize costs and realized cost efficiencies between business units.<figure class="image"><a href="https://stocktwits.com/symbol/BIDU"><img style="aspect-ratio:637/188;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bidu_sentiment_bf502ab31c.png" alt="bidu-sentiment.png" width="637" height="188"></a><figcaption>NVDA sentiment and message volume November 21, 2024, as of 10:35 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward Baidu stock stayed 'bullish’ (61/100), with message volume spiking to 'extremely high.'Baiidu was among the top 10 trending stocks on Stocktwits on&nbsp;Thursday.Some retailers on&nbsp;the platform lamented over the company’s lack of shareholder return policy. Others said the stock is undervalued.Baidu's ADS listed on Nasdaq fell 6.98% to $80.69. It is down more than 27% so far this year amid the fundamental woes and general caution toward Chinese stocks.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-ceo-jensen-huang-weighs-in-on-tariff-threat/cJIT8NfRX1">Nvidia CEO Commits To Trump Policy Support, Reveals Strategy To Offset Tariff Challenges: Retail Stays Bullish</a>

Baidu said it remains steadfast in its AI-focused strategy and is confident in its long-term trajectory. 

Baidu Stock Pulls Back On Mixed Q3 Results: Retail Applauds Company’s Positive Long-Term Commentary

Baidu said the ongoing weakness in the online marketing business was offset by the growth of its AI Cloud business.

Trip.com Holdings Limited (<a class="mention" data-mention="$TCOM" data-symbol-id="TCOM" href="https://stocktwits.com/symbol/TCOM" target="_blank">$TCOM</a>), a one-stop travel platform, is scheduled to report its third-quarter results after the market closes on Monday.Shanghai, China-based Trip.com’s quarterly earnings per share (EPS) is widely expected to decline from $1.10 in 2023 to $0.96 in 2024. The consensus, however, models an increase in revenue from $1.93 billion to $2.18 billion.&nbsp;&nbsp;In the preceding quarter, Trip.com’s revenue climbed 14% year-over-year (YoY), with the company attributing the growth to strong travel demand, especially cross-border travel. Adjusted earnings before interest, taxes and depreciation climbed about 19%.On the second-quarter earnings call, co-founder and executive chair of the board Jianzhang Liang said, "We are committed to harnessing the power of AI and unlocking its full potential, ensuring we deliver exceptional value and continuous innovation to meet the evolving needs of our customers."In June, the company launched its AI-powered 2024 Trip.Best Global and Asia 100 lists which are based on real user reviews and year-round sales popularity.&nbsp;CEO Jie Sun highlighted the resilience of the Chinese travel market and said the travel market will see robust growth following a strong start in 2024.Data from Statista&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statista.com/statistics/1215457/most-visited-travel-and-tourism-websites-worldwide/">showed</a> that Trip.com was the fourth-most visited website worldwide in October, with 100.83 million visitors compared to Booking Holdings, Inc.’s (<a class="mention" data-mention="$BKNG" data-symbol-id="BKNG" href="https://stocktwits.com/symbol/BKNG" target="_blank">$BKNG</a>) 528.03 millionThe anticipated economic recovery in China on the back of copious stimuli from the government and the central bank should bode well for the company.Last week, BofA raised the price target for Trip.com stock from $56 to $67, assuming a 20-30% rise in non-GAAP profit for the 2024-25 period due to efficiency measures implemented by the company and its strong operating leverage.Ahead of it, Mizuho Securities bumped up the price target from $65 to $78, citing China’s stimulus policies. Despite a mixed outlook due to tariff threats and the structural challenges faced by the Chinese economy, the firm remained positive about outbound travel demand in China.&nbsp;Trip.com shares have rallied over 65% for the year-to-date period. They ended Friday’s session down 0.73% at $59.49.Commenting on the Stocktwits platform, an options trader said Trip.com shares have notable relative strength among Chinese ADRs.<stembedurl>https://stocktwits.com/ivanhoff/message/591135201</stembedurl>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chinese-urban-air-mobility-company-ehang-is-due-to-report-q3-2024-results/cJ4HqbIRQc">Chinese Flying Taxi Company EHang Expected To Report Strong Revenue Growth In Q3: Retail Sentiment Soars</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Trip.com shares have gained over 65% for the year. 

Trip.com Analysts Optimistic Amid Robust Travel Trends In China As Stock Looks To Extend Strong Gains For Year 

Mizuho’s optimism regarding Trip.com is premised on strong outbound travel trends in China despite the domestic economy’s structural challenges and the looming tariff threat.

Shares of Europe’s largest airline Ryanair Holdings fell nearly 14% during Friday’s pre-market session after the firm reported a 46% year-over-year (YoY) decline in its first quarter profits at €360 million (~$392 million). The airline said that despite a 10% rise in traffic, profit was hit as the key Easter holiday fell in the previous quarter and this quarter’s airfares remained weaker than expected.Even amid the lackluster earnings report, retail investors on Stocktwits remained bullish (57/100) supported by extremely high message volumes.<figure class="image"><img style="aspect-ratio:777/222;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_22_at_8_54_34_AM_40f62fb3b4.png" alt="Retail sentiment remains bullish on Ryanair despite lackluster earnings." width="777" height="222"><figcaption>Retail sentiment remains bullish on Ryanair despite lackluster earnings</figcaption></figure>Ryanair said that total revenue declined 1% to €3.63 billion while operating costs increased 11% to €3.26 billion, marginally ahead of traffic growth. Meanwhile, average fare fell by 15% YoY €41.93.The airline expects FY25 traffic to grow 8% from 198 million to 200 million passengers, if Boeing delivery delays do not worsen. Ryanair also believes that while second quarter demand is strong, pricing remains softer than its expectations due to higher domestic capacity. It now anticipates Q2 fares to be materially lower than last summer vs. its earlier expectation of flat to modest gains.On the positive side, the airline is operating its largest ever schedule this summer, with over 200 new routes and five new bases.Ryanair Group CEO Michael O’Leary said In the last 10 days of June, the airline suffered a significant deterioration in European ATC capacity which caused multiple flight delays and cancellations, especially on first wave morning flights. This makes it “more urgent than ever that the new EU Commission and Parliament deliver long delayed reform of Europe’s hopelessly inefficient ATC services,” he said in a statement.Following the disappointing earnings announcement, shares of other European airlines also took a hit. Shares of easy Jet and Wizz Air Holdings fell over 8% on Monday. International Consolidated Airlns Grp, which runs British Airways, also dipped more than 3%.With today’s decline, Ryanair shares are now down more than 20% YTD and over 35% from their all-time highs set in April. Still, retail investors remain bullish on the travel portion of the economy and are betting that shares will regain altitude at some point in the near future.

Ryanair Profits Nearly Halve In June Quarter: But Retail Bets On A Turnaround

The airline said that despite a 10% rise in traffic, profit was hit as airfares remained weaker than expected and Easter fell in the previous quarter. 

The airline said that despite a 10% rise in traffic, profit was hit as airfares remained weaker than expected and Easter fell in the previous quarter. Despite the lackluster earnings, retail investors on Stocktwits remained bullish (57/100) supported by extremely high message volumes.

Current Price	$36.70
Prev Close	$37.44
Open	$36.78
Dividend Yield	N/A
50-Day Moving Average	$38.32
Beta	N/A
Avg. Volume	260,127.41
PE Ratio	N/A

52-Week High	$39.57
52-Week Low	$24.89
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

QQQJ
Invesco NASDAQ Next Gen 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQQJ News

QQQJInvesco NASDAQ Next Gen 100 ETF